N-acetyltransferase 2 (NAT2) gene polymorphisms in Parkinson's disease

BMC Medical Genetics

Table 2 NAT2 genotypes in controls and patients with Parkinson's disease

Genotypes			Deduced phenotypes	Controls		Parkinson's disease		Odds ratios (95% confidence interval)	χ²
c.481 C>T	c.590 G>A	c.857 G>A		n = 243	95% CI	n = 124	95% CI
CC	GG	GG	rapid	5.4 % (13)	2.9 – 9.0	9.7 % (12)	5.1 – 16.3	1.90 (0.85–4.25)	NS
CT			rapid	23.0 % (56)	17.9–28.9	25.0 % (31)	17.7 – 33.6	1.11 (0.67–1.84)	NS
	GA		rapid	8.6 % (21)	5.4 – 12.9	15.3 % (19)	9.5 – 22.9	1.91 (0.99–3.68)	p < 0.01
		GA	rapid	0.4 % (1)	0.01 – 2.3	ND	0.0 – 2.9	0.000*	NS
TT			slow¹	22.2 % (54)	17.2 – 28.0	20.2 % (25)	13.5 – 28.3	0.88 (0.52–1.51)	NS
	AA		slow	9.5 % (23)	6.1 – 13.9	5.7 % (7)	2.3 – 11.3	0.57 (0.24–1.36)	NS
	AA	GA	slow	4.1 % (10)	2.0 – 7.4	3.2 % (4)	0.9 – 8.1	0.78 (0.24–2.53)	NS
CT	GA		slow	23.9 % (58)	18.7 – 29.7	17.0 % (21)	10.8 – 24.7	0.65 (0.37–1.13)	NS
CT		GA	slow	2.5 % (6)	0.9 – 5.3	2.4 % (3)	0.5 – 6.9	0.98 (0.24–3.99)	NS
	GA	GA	slow	0.4 % (1)	0.01 – 2.3	0.8 % (1)	0.02 – 4.4	1.97 (0.13–30.24)	NS
		AA	slow	ND	0.0 – 1.5	0.8 % (1)	0.02 – 4.4	*	NS

^*The confidence intervals for the percentages were computed according to Pearson-Clopper, whereas confidence intervals for the odds ratios were computed assuming asymptotic log normality. To avoid undefined results, some estimates were not computed.
¹c.481 C>T is a silent mutation associated also with NAT2*12C (c.481 C>T, c.803A>G) and which is a rapid allele (see Hein et al. [7] )

ISSN: 1471-2350